Listed

Standard Biotools Inc.

LABNasdaqCIK 1162194HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$20.1mRevenue, Q2 FY2026, three months to 2026-06-30$20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$20.1mRevenue, Q2 FY2026, three months to 2026-06-30$20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure−7.6% on a year earlier
  • Gross margin52.4%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $10.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure+3.6 pts on a year earlier
  • Operating margin−126.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$25.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure−8.2 pts on a year earlier
  • Net margin−133.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure+20.7 pts on a year earlier
  • Diluted EPS−$0.07Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure+22.2% on a year earlier
  • Free cash flow−$10.7mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-335103. Derived: 6-month figure less the 3-month figure.Capital expenditure: $344.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-335103. Derived: 6-month figure less the 3-month figure.Report this figure+52.8% on a year earlier

Last eight quarters

Full statements
Revenue$20.1mGross margin 52.4%
Diluted EPS−$0.07, Q2 FY2026
Free cash flow−$10.7m, Q2 FY2026
Standard Biotools Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m22.1Revenue, Q3 FY2024, three months to 2024-09-30$22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure24.8Revenue, Q4 FY2024, three months to 2024-12-31$24.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure20.2Revenue, Q1 FY2025, three months to 2025-03-31$20.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure21.8Revenue, Q2 FY2025, three months to 2025-06-30$21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure19.6Revenue, Q3 FY2025, three months to 2025-09-30$19.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure23.8Revenue, Q4 FY2025, three months to 2025-12-31$23.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure21.1Revenue, Q1 FY2026, three months to 2026-03-31$21.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure20.1Revenue, Q2 FY2026, three months to 2026-06-30$20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure
Gross margin%54.9%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $12.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Revenue: $22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure45.8%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $11.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Revenue: $24.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure54.6%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $11.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Revenue: $20.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure48.8%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $10.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure48.5%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $9.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Revenue: $19.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure47.8%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $11.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Revenue: $23.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure53.5%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $11.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Revenue: $21.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure52.4%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $10.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure
Operating margin%(120.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$26.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Revenue: $22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure(105.3%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$26.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Revenue: $24.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure(133.4%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$27.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Revenue: $20.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(118.1%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$25.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure(168.5%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$32.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Revenue: $19.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure(103.6%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$24.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Revenue: $23.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure(59.1%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$12.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Revenue: $21.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(126.3%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$25.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure
Net margin%(122.0%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$26.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Revenue: $22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure(137.5%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$34.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Revenue: $24.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure(128.7%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(153.7%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$33.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $21.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure(177.4%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$34.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Revenue: $19.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figure81.0%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $19.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Revenue: $23.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure600.9%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $127.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $21.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(133.1%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$26.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Revenue: $20.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure
Diluted EPS$ per share(0.07)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figurenot reported (Diluted EPS not reported)(0.07)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(0.09)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure(0.09)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-264695.Report this figurenot reported (Diluted EPS not reported)0.33Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(0.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-335103.Report this figure
Free cash flow$m(30.1)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$27.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-264695. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-264695. Derived: 9-month figure less the 6-month figure.Report this figure(17.4)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$14.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Capital expenditure: $3.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure(35.3)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$30.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Capital expenditure: $5.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(22.6)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$20.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-335103. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-335103. Derived: 6-month figure less the 3-month figure.Report this figure(23.1)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$22.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-264695. Derived: 9-month figure less the 6-month figure.Capital expenditure: $886.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-264695. Derived: 9-month figure less the 6-month figure.Report this figure(1.7)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Capital expenditure: $476.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108326. Derived: 12-month figure less the 9-month figure.Report this figure(47.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$46.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Capital expenditure: $570.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-06, accession 0001193125-26-208967.Report this figure(10.7)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-335103. Derived: 6-month figure less the 3-month figure.Capital expenditure: $344.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-335103. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$85.3mGross margin 49.9%
Diluted EPS−$0.20, FY2025
Free cash flow−$82.6m, FY2025
Standard Biotools Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m131Revenue, FY2021, twelve months to 2021-12-31$130.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-14, accession 0001162194-23-000013.Report this figure97.9Revenue, FY2022, twelve months to 2022-12-31$97.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-036608.Report this figure106Revenue, FY2023, twelve months to 2023-12-31$106.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure91.0Revenue, FY2024, twelve months to 2024-12-31$91.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure85.3Revenue, FY2025, twelve months to 2025-12-31$85.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure
Gross margin%not reported (Gross profit not reported)37.8%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $37.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-03-11, accession 0000950170-25-036608.Revenue: $97.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-036608.Report this figure47.4%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $50.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $106.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure49.3%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $44.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $91.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure49.9%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $42.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $85.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure
Operating margin%(51.7%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$67.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-14, accession 0001162194-23-000013.Revenue: $130.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-14, accession 0001162194-23-000013.Report this figure(118.6%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$116.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-036608.Revenue: $97.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-036608.Report this figure(72.0%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$76.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $106.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(140.1%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$127.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $91.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(129.2%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$110.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $85.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure
Net margin%(45.4%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$59.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-14, accession 0001162194-23-000013.Revenue: $130.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-14, accession 0001162194-23-000013.Report this figure(194.1%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$190.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-11, accession 0000950170-25-036608.Revenue: $97.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-11, accession 0000950170-25-036608.Report this figure(70.2%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$74.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $106.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(152.6%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$138.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $91.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(87.8%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$74.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-108326.Revenue: $85.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure
Diluted EPS$ per share(0.78)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-14, accession 0001162194-23-000013.Report this figure(2.43)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-11, accession 0000950170-25-036608.Report this figure(0.94)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(0.52)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(0.20)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure
Free cash flow$m(57.3)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$44.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-14, accession 0001162194-23-000013.Capital expenditure: $13.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-14, accession 0001162194-23-000013.Report this figure(93.2)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$89.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-11, accession 0000950170-25-036608.Capital expenditure: $3.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-11, accession 0000950170-25-036608.Report this figure(46.1)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$43.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108326.Capital expenditure: $2.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(152)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$143.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108326.Capital expenditure: $8.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure(82.6)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$74.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-108326.Capital expenditure: $8.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-16, accession 0001193125-26-108326.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Standard Biotools Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Casdin Capital, LLC2026-06-30$73.0m88,783,856Unchanged
VIKING GLOBAL INVESTORS LP2026-06-30$48.3m58,651,170Unchanged
MAK CAPITAL ONE LLC2026-06-30$23.7m28,813,904Added+2,641,278
Long Focus Capital Management, LLC2026-06-30$19.3m23,500,000Added+7,484,279
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$10.1m12,252,998Reduced−563,072
BlackRock, Inc.2026-06-30$6.8m8,254,443Reduced−16,501,641
Hollow Brook Wealth Management LLC2026-06-30$4.5m5,503,381Reduced−150,000
NEUBERGER BERMAN GROUP LLC2026-06-30$4.0m4,958,620Added+301,035
Qube Research & Technologies Ltd2026-06-30$4.0m4,820,463Added+4,116,056
ROYCE & ASSOCIATES LP2026-06-30$3.7m4,525,333Added+1,519,804

Recent filings

All 1,567 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Standard Biotools Inc., recent filings
FiledFormWhat it isAccession number
2026-10-0520:16 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-26-038624
2026-09-3021:27 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-26-038110
2026-08-0520:10 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-335103
2026-08-0520:10 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-335106
2026-07-2912:15 ET8-K/A9.01 Financial statements and exhibits0001140361-26-029964
2026-07-2812:20 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-26-029841
2026-07-2420:38 ET8-K3.01 Delisting notice0001193125-26-316183
2026-06-1820:30 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-26-275946
2026-06-1221:35 ETSCHEDULE 13DOwnership report, active investor0000905148-26-002940
2026-06-0921:41 ETSCHEDULE 13D/AOwnership report, active investor, amended0000919574-26-003923

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 16, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1162194
Tickers
LAB
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer
Former names
FLUIDIGM CORP (to 2022-04-01)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.